Forest Ray

Articles Authored by Forest Ray
The firm is developing prognostic cancer tests targeting "master driver" genes that control cancer-related biological pathways.
Blood Test From Stanford-led Team Could Predict Vaccine Durability
Bone marrow cells called megakaryocytes produce platelets with transcriptional programs that enhance antibody response times to several vaccines.

Volition Eyes East Asia Expansion With Nucleosome-Based Blood Test for Lung Cancer Screening
Premium
The firm hopes to include its lung cancer assay in Taiwan's national cancer screening program while developing sepsis and ovarian cancer assays.
Biobanks have been making strides in gathering data from more diverse populations this year while the evidence for the clinical utility of embryo PRS testing remains insufficient.
Pharmacogenomics Testing Buoys Myriad Genetics Q3 Revenues While Coverage Remains an Open Question
Premium
Year-over-year pharmacogenomics testing revenues rose 34 percent, but $40 million could be at stake down the road if a decision by UnitedHealthcare goes into effect next year.
CareDx Raises Full-Year Guidance as Q3 Revenues Grow 23 Percent
Quarterly revenue gains were driven by a 27 percent year-over-year increase in testing services revenue.
Natera Wins Permanent Injunction to Prevent Sales of NeoGenomics RaDaR Assay in the US
The order is part of a settlement between the two companies and follows a preliminary injunction that the same court granted Natera in December of last year.
Following a lung cancer study, the firm plans to initiate similar studies in other cancers and to launch a new tumor profiling assay later this year.
Observation alone resulted in positive outcomes for MRD-negative patients, whereas MRD-positive individuals may still need adjuvant chemotherapy.
The nonprofit behind the work aims to bring the test to market in the next 18 to 24 months and is in discussions with potential commercialization partners.
